reports
Vetoquinol: 2 directors
Two Directors at Vetoquinol sold/bought 9,860 shares at 75.000EUR. The significance rating of the trade was 87/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
Voltalia SA: Total number of shares and voting rights in the share cap...
Voltalia SA: Total number of shares and voting rights in the share capital as of June 30, 2025 Total number of shares and voting rights in the share capital as of June 30, 2025 (Articles L. 233-8 (II) of the French Commercial Code and 223-16 of the General Regulations of the French Financial Markets Authority) Date Total number of shares in the capital Number of theoretical voting rights Number of exercisable voting rights 06/30/2025 131 318 716220 406 383219 988 392 Next on the agenda: Q2 2025 Turnover, July 23, 2025 (after market close) About Voltalia ()Voltalia is an international pl...
Voltalia SA : Nombre total de droits de vote et d’actions composant le...
Voltalia SA : Nombre total de droits de vote et d’actions composant le capital en date du 30 juin 2025 Nombre total de droits de vote et d’actions composant le capital en date du 30 juin 2025 (Art. L. 233-8 (II) du Code de Commerce et Art. 223-16 du Règlement Général de l’AMF) Date Nombre d’actions composant le capital Nombre de droits de vote théoriques Nombre de droits de vote exerçables 30/06/2025 131 318 716220 406 383219 988 392 Prochain rendez-vous : Chiffre d’affaires du 2ème trimestre 2025, le 23 juillet 2025 (après Bourse) A propos de Voltalia ()Voltalia est un acteur internation...
Voltalia SA: Half-year statement of the liquidity contract as of June ...
Voltalia SA: Half-year statement of the liquidity contract as of June 30, 2025 Half-year statement of the liquidity contract As of June 30, 2025 Voltalia (Euronext Paris, ISIN code: FR0011995588), announces that the Company’s liquidity account, which is managed by NATEXIS ODDO BHF under a liquidity contract, included the following cash and Company common shares as of June 30, 2025: 32,669 shares €697,040Number of transactions on buy side over the period: 2,715Number of transactions on sell side over the period: 2,851Volume traded on buy side over the period: 597,704 shares for €4,583,68...
Voltalia SA : Bilan semestriel du contrat de liquidité au 30 juin 2025
Voltalia SA : Bilan semestriel du contrat de liquidité au 30 juin 2025 Bilan semestriel du contrat de liquidité Au 30 juin 2025 Voltalia (Euronext Paris, code ISIN : FR0011995588), annonce qu’au titre du contrat de liquidité confié par la Société à NATIXIS ODDO BHF, les moyens suivants figuraient au compte de liquidité à la date du 30 juin 2025 : 32 669 titres697 040 euros Nombre de transactions exécutées sur le semestre à l'achat : 2 715Nombre de transactions exécutées sur le semestre à la vente : 2 851Volume échangé sur le semestre à l'achat : 597 704 titres pour 4 583 680 eur...
DBV Technologies Announces First Subject Screened in COMFORT Toddlers ...
DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old Châtillon, France, June 25, 2025 DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old First subject screened at the Respiratory Medicine Research Institute of Michigan with Dr. Jeffrey Leflein acting as Principal InvestigatorAdditional sites, including Allergy and Asthma Center of Minnesota and Hamilton Allergy and Immunology Clinic of Ontario, Canada have been act...
DBV Technologies annonce le screening du premier sujet de l'étude comp...
DBV Technologies annonce le screening du premier sujet de l'étude complémentaire d’innocuité COMFORT Toddlers chez les enfants âgés de 1 à 3 ans allergiques à l’arachide. Châtillon, France, le 25 juin (22 :30 CEST) 2025 DBV Technologies annonce le screening du premier sujet de l'étude complémentaire d’innocuité COMFORT Toddlers chez les enfants âgés de 1 à 3 ans allergiques à l’arachide. Screening du premier sujet à l'Institut de recherche en médecine respiratoire du Michigan, sous la direction du Dr Jeffrey Leflein, investigateur principal.D'autres sites ont été activés et prévoient des...
- Thomas Vranken
Amoéba Exemption from obligation to destroy trial crops in France
The French regulator ANSES has granted an exemption for Amoéba's biocontrol product Axpera, allowing crop trials without the usual requirement to destroy the harvest. This exemption, which applies to both open-field and greenhouse crops affected by various diseases, supports ongoing evaluations and follows recent regulatory milestones in France and the EU. While no material commercial sales are expected yet in 2025, the move is seen as another strong endorsement of Amoéba's innovative technology...
- Jeremy Garnier
ODDO : ODDO BHF Nextcap Forum: Feedback from day two
Feedback of the companies present at the ODDO BHF Nextcap Forum Company Country Market cap. (m) Company Country Market cap. (m) Accsys Technologies € 124 Hoffmann Green € 62 Afyren € 72 Hornbach € 1 451 Altri € 1 058 IDI € 537 AMG € 550 Implenia CHF 973 AmRest PLN 3 544 Jacquet Metals € 494 Arcure € 29 Kloeckner & Co € 653 Arverne 194 Knaustabbert € 144 Austriacard Holdings € 188 Lna Santé € 270 Bastide € 218 Medincell € 398 Befesa € 1 116 Nacon € 63 CAF € 1 649 N...
NXI NEXITY SA CLASS A
UNIQA INSURANCE GROUP AG
BLC BASTIDE LE CONFORT MEDICAL SA
KCO KLOECKNER & CO SE
ALTR ALTRI SGPS SA
SWP SWORD GROUP SE
CGM CEGEDIM SA
EKI EKINOPS SA
VLS VALNEVA SE
LNA LNA SANTE SA
JCQ JACQUET METALS SA
ELG ELMOS SEMICONDUCTOR SE
ALCAR CARMAT SA
TPE PVA TEPLA AG
QDT QUADIENT SA
IMPN IMPLENIA AG
IDIP INSTITUT DE DEVELOPPEMENT INDUSTRIEL SCA
COR CORTICEIRA AMORIM SGPS SA
HEIJM HEIJMANS N.V. CERT
PAL
RIEN PALFINGER AG
AMG RIETER HOLDING AG
EDR AMG ADVANCED METALLURGICAL GROUP N.V.
ZAG EDREAMS ODIGEO SA
POST ZUMTOBEL GROUP AG
INSD OSTERREICHISCHE POST AG
FACC VERIMATRIX SA
AXS FACC AG
HBH ACCSYS TECHNOLOGIES
TRE HORNBACH HOLDING AG & CO. KGAA
SMCP TECNICAS REUNIDAS SA
BFSA SMCP SA
VOS BEFESA SA
CAF VOSSLOH AG
MEDCL CONSTRUCCIONES Y AUXILIAR DE FERROCARRILES S.A.
EAT MEDINCELL SA
GRE AMREST HOLDINGS SE
ALCUR GRENERGY RENOVABLES
FQT ARCURE SA
CLA FREQUENTIS AG WIENER
S30 CLARANOVA SE
ALHGR SOLUTIONS 30 SE
NACON HOFFMANN GREEN CEMENT TECHNOLOGIES SA
KTA NACON SASU
UPG KNAUS TABBERT
ALAFY UNIFIEDPOST GROUP
FORSE AFYREN
WAGA FORSEE POWER SA
EAPI WAGA ENERGY SA
ACAG EUROAPI
ARVEN AUSTRIACARD HOLDINGS AG
ORP ARVERNE GROUP SA
LOCAL ORPEA
SOLOCAL GROUP
- Thomas Vranken
Amoéba EU approval for Axpera's active substance
Amoéba has received final approval from the European Commission for the active substance of its biocontrol product, Axpera, marking it as a low-risk substance. This milestone concludes a five-year EU validation process and positions the company for commercialisation in Europe, with marketing authorisation applications underway in nine countries and decisions expected by late 2025/early 2026. We maintain a Buy rating with € 1.8 TP.
- Emira Sagaama
- Jeremy Garnier
- Steven Boumans
ALFOC FOCUS HOME INTERACTIVE SA
DGE DIAGEO PLC
RI PERNOD RICARD SA
NXI NEXITY SA CLASS A
RCO REMY COINTREAU SA
UNIQA INSURANCE GROUP AG
BLC BASTIDE LE CONFORT MEDICAL SA
KCO KLOECKNER & CO SE
ALTR ALTRI SGPS SA
SWP SWORD GROUP SE
CGM CEGEDIM SA
BLND BRITISH LAND COMPANY PLC
EKI EKINOPS SA
VLS VALNEVA SE
LNA LNA SANTE SA
JCQ JACQUET METALS SA
ELG ELMOS SEMICONDUCTOR SE
ALCAR CARMAT SA
SDF K+S AG
TPE PVA TEPLA AG
QDT QUADIENT SA
IMPN IMPLENIA AG
IDIP INSTITUT DE DEVELOPPEMENT INDUSTRIEL SCA
COR CORTICEIRA AMORIM SGPS SA
HEIJM HEIJMANS N.V. CERT
PAL
TEG PALFINGER AG
RIEN TAG IMMOBILIEN AG
CCC RIETER HOLDING AG
AMG CCC SA
EDR AMG ADVANCED METALLURGICAL GROUP N.V.
ZAG EDREAMS ODIGEO SA
POST ZUMTOBEL GROUP AG
INSD OSTERREICHISCHE POST AG
FACC VERIMATRIX SA
AXS FACC AG
HBH ACCSYS TECHNOLOGIES
TRE HORNBACH HOLDING AG & CO. KGAA
SMCP TECNICAS REUNIDAS SA
BFSA SMCP SA
LAND BEFESA SA
VOS LAND SECURITIES GROUP PLC
CAF VOSSLOH AG
MEDCL CONSTRUCCIONES Y AUXILIAR DE FERROCARRILES S.A.
EAT MEDINCELL SA
GRE AMREST HOLDINGS SE
ALCUR GRENERGY RENOVABLES
FQT ARCURE SA
CLA FREQUENTIS AG WIENER
S30 CLARANOVA SE
ALHGR SOLUTIONS 30 SE
NACON HOFFMANN GREEN CEMENT TECHNOLOGIES SA
CPR NACON SASU
KTA DAVIDE CAMPARI-MILANO N.V.
UPG KNAUS TABBERT
ALAFY UNIFIEDPOST GROUP
FORSE AFYREN
WAGA FORSEE POWER SA
EAPI WAGA ENERGY SA
ACAG EUROAPI
ARVEN AUSTRIACARD HOLDINGS AG
ORP ARVERNE GROUP SA
LOCAL ORPEA
SOLOCAL GROUP
- Emira Sagaama
- Jeremy Garnier
- Martial Descoutures
DGE DIAGEO PLC
RNO RENAULT SA
RI PERNOD RICARD SA
NXI NEXITY SA CLASS A
RCO REMY COINTREAU SA
UNIQA INSURANCE GROUP AG
BLC BASTIDE LE CONFORT MEDICAL SA
KCO KLOECKNER & CO SE
ALTR ALTRI SGPS SA
SWP SWORD GROUP SE
CGM CEGEDIM SA
COLR ETABLISSEMENTEN FRANZ COLRUYT N.V.
EKI EKINOPS SA
VLS VALNEVA SE
LNA LNA SANTE SA
JCQ JACQUET METALS SA
VNA VONOVIA SE
ELG ELMOS SEMICONDUCTOR SE
ALCAR CARMAT SA
TPE PVA TEPLA AG
QDT QUADIENT SA
IMPN IMPLENIA AG
IDIP INSTITUT DE DEVELOPPEMENT INDUSTRIEL SCA
COR CORTICEIRA AMORIM SGPS SA
HEIJM HEIJMANS N.V. CERT
PAL
RIEN PALFINGER AG
AMG RIETER HOLDING AG
EDR AMG ADVANCED METALLURGICAL GROUP N.V.
ZAG EDREAMS ODIGEO SA
POST ZUMTOBEL GROUP AG
INSD OSTERREICHISCHE POST AG
FACC VERIMATRIX SA
AXS FACC AG
HBH ACCSYS TECHNOLOGIES
TRE HORNBACH HOLDING AG & CO. KGAA
SMCP TECNICAS REUNIDAS SA
BFSA SMCP SA
VOS BEFESA SA
BESI VOSSLOH AG
CAF BE SEMICONDUCTOR INDUSTRIES N.V.
MEDCL CONSTRUCCIONES Y AUXILIAR DE FERROCARRILES S.A.
EAT MEDINCELL SA
GRE AMREST HOLDINGS SE
ALCUR GRENERGY RENOVABLES
FQT ARCURE SA
CLA FREQUENTIS AG WIENER
S30 CLARANOVA SE
ALHGR SOLUTIONS 30 SE
BNTX HOFFMANN GREEN CEMENT TECHNOLOGIES SA
NACON BIONTECH SE
CPR NACON SASU
KTA DAVIDE CAMPARI-MILANO N.V.
UPG KNAUS TABBERT
ALAFY UNIFIEDPOST GROUP
FORSE AFYREN
WAGA FORSEE POWER SA
EAPI WAGA ENERGY SA
ACAG EUROAPI
ARVEN AUSTRIACARD HOLDINGS AG
ORP ARVERNE GROUP SA
LOCAL ORPEA
SOLOCAL GROUP
- Emira Sagaama
- Jeremy Garnier
- Steven Boumans
ALFOC FOCUS HOME INTERACTIVE SA
DGE DIAGEO PLC
RI PERNOD RICARD SA
NXI NEXITY SA CLASS A
RCO REMY COINTREAU SA
UNIQA INSURANCE GROUP AG
BLC BASTIDE LE CONFORT MEDICAL SA
KCO KLOECKNER & CO SE
ALTR ALTRI SGPS SA
SWP SWORD GROUP SE
CGM CEGEDIM SA
BLND BRITISH LAND COMPANY PLC
EKI EKINOPS SA
VLS VALNEVA SE
LNA LNA SANTE SA
JCQ JACQUET METALS SA
ELG ELMOS SEMICONDUCTOR SE
ALCAR CARMAT SA
SDF K+S AG
TPE PVA TEPLA AG
QDT QUADIENT SA
IMPN IMPLENIA AG
IDIP INSTITUT DE DEVELOPPEMENT INDUSTRIEL SCA
COR CORTICEIRA AMORIM SGPS SA
HEIJM HEIJMANS N.V. CERT
PAL
TEG PALFINGER AG
RIEN TAG IMMOBILIEN AG
CCC RIETER HOLDING AG
AMG CCC SA
EDR AMG ADVANCED METALLURGICAL GROUP N.V.
ZAG EDREAMS ODIGEO SA
POST ZUMTOBEL GROUP AG
INSD OSTERREICHISCHE POST AG
FACC VERIMATRIX SA
AXS FACC AG
HBH ACCSYS TECHNOLOGIES
TRE HORNBACH HOLDING AG & CO. KGAA
SMCP TECNICAS REUNIDAS SA
BFSA SMCP SA
LAND BEFESA SA
VOS LAND SECURITIES GROUP PLC
CAF VOSSLOH AG
MEDCL CONSTRUCCIONES Y AUXILIAR DE FERROCARRILES S.A.
EAT MEDINCELL SA
GRE AMREST HOLDINGS SE
ALCUR GRENERGY RENOVABLES
FQT ARCURE SA
CLA FREQUENTIS AG WIENER
S30 CLARANOVA SE
ALHGR SOLUTIONS 30 SE
NACON HOFFMANN GREEN CEMENT TECHNOLOGIES SA
CPR NACON SASU
KTA DAVIDE CAMPARI-MILANO N.V.
UPG KNAUS TABBERT
ALAFY UNIFIEDPOST GROUP
FORSE AFYREN
WAGA FORSEE POWER SA
EAPI WAGA ENERGY SA
ACAG EUROAPI
ARVEN AUSTRIACARD HOLDINGS AG
ORP ARVERNE GROUP SA
LOCAL ORPEA
SOLOCAL GROUP
DBV Technologies to Participate in Upcoming EAACI Congress 2025
DBV Technologies to Participate in Upcoming EAACI Congress 2025 Châtillon, France, June 12, 2025 DBV Technologies to Participate in Upcoming EAACI Congress 2025 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced upcoming participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress, June 13 – 16, 2025, in Glasgow, United Kingdom. DBV will present two posters and will also host a symposium and exhibit booth in the EAACI exhibit hall. Data to be presen...
DBV Technologies participera au prochain congrès EAACI 2025
DBV Technologies participera au prochain congrès EAACI 2025 Châtillon, France, le 12 juin (22:30 CEST) 2025 DBV Technologies participera au prochain congrès EAACI 2025 DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market: DBVT ; CUSIP : 23306J309), une société biopharmaceutique en phase clinique, annonce aujourd'hui sa participation au congrès European Academy of Allergy and Clinical Immunology (EAACI) qui se tiendra du 13 au 16 juin 2025 à Glasgow, au Royaume-Uni. DBV présentera deux posters, organisera un symposium et tiendra un stand dans le hall d'exposition d...
DBV Technologies Announces the Voting Results of its 2025 Combined Gen...
DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting Châtillon, France, June 11, 2025 DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the “Company”), held its Combined General Meeting (the “General Meeting”). The General Meeting was chaired by Michel de Rosen, Chairman of the Company. The Company’s shareholders approved all resolutions submitted by t...
DBV Technologies annonce les résultats de son Assemblée Générale Mixte...
DBV Technologies annonce les résultats de son Assemblée Générale Mixte 2025 Châtillon, France, le 11 juin 2025 DBV Technologies annonce les résultats de son Assemblée Générale Mixte 2025 Toutes les résolutions proposées à l’Assemblée Générale ont été adoptées DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market : DBVT), (la « Société »), société biopharmaceutique en phase clinique, a tenu son Assemblée Générale Mixte (l’« Assemblée Générale »). L’Assemblée Générale s’est déroulée au siège social de la Société, sous la présidence de Michel de Rosen, Président du C...
Abivax Announces Results of its June 6, 2025 Annual General Meeting
Abivax Announces Results of its June 6, 2025 Annual General Meeting Abivax Announces Results of its June 6, 2025 Annual General Meeting PARIS, France, June 11, 2025, 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, held its annual general meeting of shareholders on June 6, 2025 (the “General Meeting”), which was chaire...
Voltalia SA: Total number of shares and voting rights in the share cap...
Voltalia SA: Total number of shares and voting rights in the share capital as of May 31, 2025 Total number of shares and voting rights in the share capital as of May 31, 2025 (Articles L. 233-8 (II) of the French Commercial Code and 223-16 of the General Regulations of the French Financial Markets Authority) Date Total number of shares in the capital Number of theoretical voting rights Number of exercisable voting rights 05/31/2025 131 318 716 220 409 933 220 004 140 Next on the agenda: Q2 2025 Turnover, July 23, 2025 (after market close) About Voltalia () Voltalia...
Voltalia SA : Nombre total de droits de vote et d’actions composant le...
Voltalia SA : Nombre total de droits de vote et d’actions composant le capital en date du 31 mai 2025 Nombre total de droits de vote et d’actions composant le capital en date du 31 mai 2025 (Art. L. 233-8 (II) du Code de Commerce et Art. 223-16 du Règlement Général de l’AMF) Date Nombre d’actions composant le capital Nombre de droits de vote théoriques Nombre de droits de vote exerçables 31/05/2025 131 318 716220 409 933220 004 140 Prochain rendez-vous : Chiffre d’affaires du 2ème trimestre 2025, le 23 juillet 2025 (après Bourse) A propos de Voltalia ()Voltalia est un acteur international...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.